You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,566,317


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,566,317
Title:Treatment of ophthalmic conditions
Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.
Inventor(s): Osio Sancho; Alberto (Mexico, D.F., MX)
Assignee: Osio Corporation (Coronado, CA)
Application Number:15/004,246
Patent Claims:1. A non-invasive method for treating an ophthalmic condition associated with an error in refraction of the eye, the method comprising steps of: providing a contact lens; providing eye drops comprising an effective amount of hyaluronidase and collagenase, wherein the collagenase is not matrix metalloproteinase 1 or matrix metalloproteinase 2; applying the contact lens to an eye of a patient suffering from the ophthalmic condition; and applying the eye drops to the eye of the patient; wherein the treatment corrects the patient's vision, and the treatment results in corrected vision for at least 6 months.

2. The method of claim 1, wherein the contact lens is an extended wear contact lens.

3. The method of claim 1, wherein the contact lens is a gas permeable contact lens.

4. The method of claim 1, wherein the contact lens is a molding contact lens.

5. The method of claim 1, wherein the treatment induces a change in the shape of the cornea.

6. The method of claim 1, wherein the treatment induces a change in the physiology and anatomy of the cornea by changing the radius of curvature of the anterior surface of the eye.

7. The method of claim 1, wherein the eye drops further comprise at least one agent selected from the group consisting of enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

8. The method of claim 1, wherein the eye drops further comprise a polymer.

9. The method of claim 8, wherein the polymer is selected from the group consisting of methylcellulose, cellulose, polyvinyl alcohol, and polyethylene glycol.

10. The method of claim 1, wherein the eye drops are hypertonic.

11. The method of claim 1, wherein the eye drops are hypotonic.

12. The method of claim 1, wherein the eye drops comprise about 0.01% to about 10% (weight percent) hyaluronidase, and about 0.01% to about 10% (weight percent) collagenase.

13. The method of claim 1, wherein the treatment results in the correction of up to 3 diopters of refractive error without surgery.

14. The method of claim 1, wherein the treatment results in the correction of up to 4 diopters of refractive error without surgery.

15. The method of claim 1, wherein the treatment results in the correction of up to 5 diopters of refractive error without surgery.

16. The method of claim 1, whereby the treatment results in corrected vision for at least 1 year.

17. The method of claim 1, wherein the ophthalmic condition is a residual refractive error present after a surgical procedure involving the eye.

18. The method of claim 17, wherein the surgical procedure is keratotomy, keratomileusis by a freezing process, automated lamellar keratomileusis, photo-reactive keratomileusis, laser-assisted in situ keratomileusis, later intrastromal keratomileusis, laser epithelial keratomileusis, conductive keratoplasty, or scleral resection.

19. The method of claim 17, wherein the surgical procedure includes cutting corneal or sclera tissue and/or ablating areas of the cornea.

20. The method of claim 1, wherein the ophthalmic condition is a genetic refractive defect.

Details for Patent 9,566,317

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2023-12-19
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2023-12-19
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2023-12-19
Akorn, Inc. HYDASE hyaluronidase Injection 021716 10/25/2005 ⤷  Try a Trial 2023-12-19
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 06/04/1965 ⤷  Try a Trial 2023-12-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.